Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly patients with colorectal cancer: A population-based propensity score-matched cohort study

Wen-Yen Chiou, Shih-Kai Hung, Hon-Yi Lin, Liang-Cheng Chen, Feng-Chun Hsu, Shiang-Jiun Tsai, Ben-Hui Yu, Moon-Sing Lee, Chung-Yi Li, Wen-Yen Chiou, Shih-Kai Hung, Hon-Yi Lin, Liang-Cheng Chen, Feng-Chun Hsu, Shiang-Jiun Tsai, Ben-Hui Yu, Moon-Sing Lee, Chung-Yi Li

Abstract

The commonly used vaccine for adults with a high risk of pneumonia is 23-valent pneumococcal polysaccharide vaccine (PPSV23). However, its effectiveness in patients with colorectal cancer has not been investigated. This study aimed to investigate the effectiveness of PPSV23 in reducing the risk of pneumonia among elderly patients with colorectal cancer.A total of 120,605 newly diagnosed patients with colorectal cancer were identified from the Taiwan National Health Insurance Research Database between 1996 and 2010. Of these patients, 18,468 were 75 years or older in 2007 to 2010, and 3515 received PPSV23. People aged 75 years or older have been considered eligible for receiving PPSV23 vaccination in Taiwan since 2007. The specific "vaccination period" of October 2008 to December 2008 was used to minimize the potential immortal time bias. Therefore, 893 patients who received PPSV23 outside this vaccination period or died before 2009 and 2960 unvaccinated patients who died before 2009 were excluded. After the propensity score was matched with a 1:3 ratio, 2622 vaccinated patients and 7866 unvaccinated patients were recruited. A multivariate log-linear Poisson regression model was performed and adjusted for potential confounders, including influenza vaccination, vaccination period, cancer treatment modalities, comorbidities, and sociodemographic variables.After 2 years of follow-up, the incidence rate of the pneumonia hospitalization of the vaccinated patients was significantly lower than that of the unvaccinated patients at 85.53 per 1000 person-years (PYs) of the former and 92.38 per 1000 PYs of the latter. The proportions of patients who had 2, 3, and >3 pneumonia hospitalizations per year were consistently lower in the vaccinated group than in the unvaccinated group (1.9% vs 2.0%, 0.5% vs 0.9%, and 0.7% vs 1.1%, respectively). After adjustment for covariates was made, PPSV23 vaccine was significantly associated with a reduced risk of pneumonia hospitalization, with an adjusted incidence rate ratio of 0.88 (P = .040). The overall pneumonia-free survival rate was also significantly higher in the vaccinated patients than in the unvaccinated patients (P = .001).PPSV23 vaccination was associated with a significantly reduced rate of pneumonia hospitalization in elderly patients with colorectal cancer.

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Study design flowchart for elderly colorectal cancer patients with and without 23-valent pneumococcal polysaccharide vaccine (PPSV23). # The “vaccination period,” October 2008 to December 2008, is set to reduce immortal time bias.
Figure 2
Figure 2
Kaplan-Meier survival curves for elderly colorectal cancer patients with and without PPSV23 vaccination (P = .001). Green line = with PPSV23 vaccination, blue line = without PPSV23 vaccination. PPSV23 = 23-valent pneumococcal polysaccharide vaccine.

References

    1. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017;66:683–91.
    1. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544–73.
    1. Report of Taiwan Cancer Registry. 2015. Available at: Cancer registry annual report, 2015, Taiwan. (last accessed 28 November 2019).
    1. Yen TT, Lin CH, Jiang RS, et al. Incidence of late-onset pneumonia in patients after treatment with radiotherapy for nasopharyngeal carcinoma: a nationwide population-based study. Head Neck 2015;37:1756–61.
    1. Lee JY, Jin SM, Lee CH, et al. Risk factors of postoperative pneumonia after lung cancer surgery. J Korean Med Sci 2011;26:979–84.
    1. Lee JO, Kim DY, Lim JH, et al. Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients. Lung Cancer 2008;62:381–4.
    1. Rabello LSCF, Silva JRL, Azevedo LCP, et al. Clinical outcomes and microbiological characteristics of severe pneumonia in cancer patients: a prospective cohort study. PLoS One 2015;10:e0120544.
    1. Schmedt N, Heuer OD, Häckl D, et al. Burden of community-acquired pneumonia, predisposing factors and health-care related costs in patients with cancer. BMC Health Serv Res 2019;19:30.
    1. Semenov YR, Starmer HM, Gourin CG. The effect of pneumonia on short-term outcomes and cost of care after head and neck cancer surgery. Laryngoscope 2012;122:1994–2004.
    1. Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011;29:3398–412.
    1. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993;270:1826–31.
    1. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453–60.
    1. Gross PA, Gould AL, Brown AE. Effect of cancer chemotherapy on the immune response to influenza virus vaccine: review of published studies. Rev Infect Dis 1985;7:613–8.
    1. Nordoy T, Aaberge IS, Husebekk A, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002;19:71–8.
    1. Berglund A, Willen L, Grodeberg L, et al. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncol 2014;53:1212–20.
    1. Braga CB, Santos IK, Palmeira P, et al. Effect of zinc supplementation on serological response to vaccination against Streptococcus pneumoniae in patients undergoing chemotherapy for colorectal cancer. Nutr Cancer 2015;67:926–32.
    1. Pritz T, Weinberger B, Grubeck-Loebenstein B. The aging bone marrow and its impact on immune responses in old age. Immunol Lett 2014;162(1 pt B):310–5.
    1. Lu JF, Hsiao WC. Does universal health insurance make health care unaffordable? Lessons from Taiwan. Health Aff (Millwood) 2003;22:77–88.
    1. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. Health Aff (Millwood) 2003;22:61–76.
    1. Bureau of National Health Insurance Website (2000) Methods for estimating false claims. Available at: [accessed date October 1, 2009).
    1. Cilloniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest 2013;144:999–1007.
    1. Liu CY, Hung YT, Chuang YL, et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag 2006;4:1–22.
    1. Chen HF, Ho CA, Li CY. Age and sex may significantly interact with diabetes on the risks of lower-extremity amputation and peripheral revascularization procedures: evidence from a cohort of a half-million diabetic patients. Diabetes Care 2006;29:2409–14.
    1. Chiou WY, Hung SK, Lai CL, et al. Effect of 23-valent pneumococcal polysaccharide vaccine inoculated during anti-cancer treatment period in elderly lung cancer patients on community-acquired pneumonia hospitalization: a nationwide population-based cohort study. Medicine (Baltimore) 2015;94:e1022.
    1. Chiou W-Y, Lee M-S, Hung S-K, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: a population-based propensity score matched cohort study. BMJ Open 2018;8:e019364–119364.
    1. Choi W, Kim JG, Beom S-H, et al. Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer: a randomized controlled trial. Cancer Research and Treatment 2019.
    1. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004;39:1642–50.
    1. Jung J, Moon SM, Jang HC, et al. Incidence and risk factors of postoperative pneumonia following cancer surgery in adult patients with selected solid cancer: results of “Cancer POP” study. Cancer Med 2018;7:261–9.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever